Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,627 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05795101 | TRUDI: TDXD+Durva in HER2+/Low IBC(TRUDI) | recruiting | Phase 2 | 63 | Filipa Lynce, MDOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06027632 | Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer(COG STIM 2) | recruiting | N/A | 300 | Centre Francois BaclesseOTHER | 1 | Sep 19, 2025 |
| clinicaltrials |
| NCT06927102 | From Exclusion to Inclusion: Analysing Follow-up Discontinuity in Breast Cancer(FOCUS-BC) | recruiting | — | 1,500 | Basavatarakam Indo American Cancer Hospital & Research InstituteOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06493864 | A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 21 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07095114 | A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients. | recruiting | N/A | 30 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT05329532 | Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer(ModiFY) | recruiting | Phase 1 / Phase 2 | 168 | Scancell LtdINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT05851677 | Disitamab Vedotin (RC48-ADC) in Breast Cancer | recruiting | — | 45 | RenJi HospitalOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178886 | Breast Reconstruction and Radiotherapy(CONRAD) | recruiting | — | 750 | Janine M. Simons MD PhDOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT03758976 | Sweden Cancerome Analysis Network - Breast Recurrence (SCAN-B-rec) | recruiting | — | 2,000 | Lund University HospitalOTHER | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06375798 | Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer | recruiting | — | 620 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07034976 | Efficacy of Non-ablative Radiofrequency Combined With Pelvic Floor Muscle Training for Genitourinary Syndrome of Menopause in Breast Cancer Survivors (RF-SGM) | recruiting | N/A | 50 | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06079983 | JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects | recruiting | Phase 3 | 400 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06537752 | A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients | recruiting | — | 1,052 | Boryung Pharmaceutical Co., LtdINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT06977360 | Feasibility, Acceptability and Preliminary Efficacy of the New Iteration of the Innovative Smartphone-based Care Solution for Women With Breast Cancer Undergoing Chemotherapy (iCareBreast+): A Pilot Study Research Proposal | recruiting | N/A | 40 | National Cancer Centre, SingaporeOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04138719 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer | recruiting | Phase 2 | 520 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04159142 | Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer | recruiting | Phase 2 | 414 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT04254263 | Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer(ATP) | recruiting | Phase 3 | 316 | RenJi HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05578053 | Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer | recruiting | — | 420 | Hebei Medical University Fourth HospitalOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05449691 | Biological Matrices Versus Synthetic Meshes(BIOSYM) | recruiting | N/A | 60 | University Hospitals of Derby and Burton NHS Foundation TrustOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07162298 | Dragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients | recruiting | Phase 2 | 72 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT05957068 | Breast Cancer Exercise Intervention Study(BREXINT) | recruiting | N/A | 2,156 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07156253 | Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 110 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT06415266 | Assessment the sExual Quality of Life in Breast Cancer Patients Receiving oncoSexology Supportive Care on Proactive Versus On-request(VENUS) | recruiting | N/A | 264 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07151911 | Real wOrld studY in the Adjuvant Setting for High Risk earLy Breast Cancer Patients(ROYAL) | recruiting | — | 100 | Azienda Ospedaliero-Universitaria di ModenaOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05900206 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer(ARIADNE) | recruiting | Phase 2 | 370 | Karolinska University HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06911970 | Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer Treatment(Immuno-Ex) | recruiting | N/A | 44 | Université de SherbrookeOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT07142096 | WinQ : a Window of Opportunity Study With MitoQ in Breast Cancer(WinQ) | recruiting | N/A | 20 | Université Catholique de LouvainOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03954431 | High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)(LowerDoseBCT) | recruiting | N/A | 600 | University of ArizonaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135661 | Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy(UPH-BC) | recruiting | N/A | 312 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07136753 | MIBREAST Making in Immediate Breast REconstruction And the Measurement of the EffectS of RadioTherapy(MIBREAST) | recruiting | — | 300 | Royal Marsden NHS Foundation TrustOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06508307 | A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors | recruiting | Phase 1 | 21 | GONGCHU Biotechnology Co., LtdOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07134153 | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases(INOVATE) | recruiting | Phase 1 / Phase 2 | 139 | Fudan UniversityOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT03053193 | MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles(FLEX) | recruiting | — | 30,000 | AgendiaINDUSTRY | 4 | Aug 20, 2025 | clinicaltrials |
| NCT07131735 | Intraoperative Detection of Breast Cancer by Electrosurgical Gas Analysis and Artificial Intelligence | recruiting | — | 30 | Pontificia Universidad Catolica de ChileOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT07071402 | A Study on the Treatment of Early Small Breast Cancer With Ultrasound-guided Vacuum-assisted Excision Combined With Surgery | recruiting | N/A | 120 | Xijing HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06590727 | Psychological Well-being in Patients With Breast Cancer(RAISE) | recruiting | — | 2,400 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT07008976 | Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer | recruiting | Phase 3 | 246 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT06830590 | Study of Molecular Characterisation of Early Operable Primary Breast Cancer in Pakistani Population(BrCa) | recruiting | — | 300 | Liaquat University of Medical & Health SciencesOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06371274 | A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. | recruiting | N/A | 29 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06700070 | A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors | recruiting | Early Phase 1 | 12 | Pure Biologics S.A.INDUSTRY | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113613 | Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | recruiting | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07108517 | A Manualized Post-Traumatic Growth Intervention for People With Cancer in Greece - IC-Growth(IC-Growth) | recruiting | N/A | 180 | Centre for Research and Technology HellasOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06002022 | Evaluation of Improvements in Patient-reported Quality of Life(REBECCA-QoL) | recruiting | N/A | 110 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07106112 | Carbon Suspension vs. Metallic Marker for Axillary Lymph Node Marking in Breast Cancer After Neoadjuvant Therapy(COMET) | recruiting | N/A | 110 | Saint Petersburg State University, RussiaOTHER | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Sep 19, 2025source: clinicaltrials